Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D for Drug Resistant Epilepsy
NCT06053281Phase 1Recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in epilepsy comparing Vitamin D with Placebo (2 arms). Primary endpoint: Percentage change of seizure frequency at 24 weeks. Started Jan 2024; status: recruiting.
02
Drugs
vitamin d
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT06053281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06053281.